Results 1 to 10 of about 11,885 (204)
Galantamine plasma concentration and cognitive response in Alzheimer’s disease [PDF]
PeerJ, 2019 Background Galantamine has been approved for the treatment of Alzheimer’s disease (AD). However, there are few studies which have reported the association between cognitive responses and galantamine plasma concentration.
Yi-Ting Lin +3 more
doaj +4 more sources
Galantamine attenuates autoinflammation in a mouse model of familial mediterranean fever
Molecular Medicine, 2022 Background Autoinflammatory diseases, a diverse group of inherited conditions characterized by excessive innate immune activation, have limited therapeutic options.
Ibrahim T. Mughrabi +10 more
doaj +2 more sources
Galantamine ameliorates hyperoxia-induced brain injury in neonatal mice
Frontiers in Neuroscience, 2023 Introduction:Prolonged oxygen therapy in preterm infants often leads to cognitive impairment. Hyperoxia leads to excess free radical production with subsequent neuroinflammation, astrogliosis, microgliosis and apoptosis. We hypothesized that Galantamine,
Nahla Zaghloul +5 more
doaj +3 more sources
Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine
Journal of Pharmacological Sciences, 2011 .: Several lines of evidence suggest that cholinergic deficits may contribute to the pathophysiology of psychiatric disorders as well as Alzheimer’s disease.
Yukio Ago +3 more
doaj +2 more sources
Galantamine ameliorates experimental pancreatitis
Molecular Medicine, 2023 Background Acute pancreatitis is a common and serious inflammatory condition currently lacking disease modifying therapy. The cholinergic anti-inflammatory pathway (CAP) is a potent protective anti-inflammatory response activated by vagus nerve-dependent
Dane A. Thompson +9 more
doaj +2 more sources
Galantamine inhibits β-amyloid aggregation and cytotoxicity
Journal of the Neurological Sciences, 2009 The ability of galantamine (Reminyl) to inhibit the aggregation and toxicity of the beta-amyloid peptide (Abeta) was investigated. Galantamine showed concentration-dependent inhibition of aggregation of both Abeta 1-40 and Abeta 1-42, as determined by an
Richard B Parsons +2 more
exaly +2 more sources
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
Clinical Interventions in Aging, 2009 Ben SeltzerGeriatric Research, Education and Clinical Center, VA Boston Healthcare System, Department of Neurology, Harvard Medical School, Boston, MA, USAAbstract: An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine ...
Ben Seltzer
doaj +1 more source
Het effect van galantamine op de ecg- geleidingstijden
Tijdschrift voor Gerontologie en Geriatrie, 2014 Achtergrond Galantamine, een acethylcholinesterase-remmer (AChE-remmer), is geregistreerd voor de symptomatische behandeling van lichte tot matig ernstige dementie van het Alzheimer-type.
I. C. Jobse, R. A. M. de Jonckheere
doaj +3 more sources
Galantamine in Alzheimer’s disease
Expert Review of Neurotherapeutics, 2008 Galantamine is a cholinesterase inhibitor with a dual mechanism of action. It is a reversible inhibitor of acetylcholine esterase and enhances the intrinsic action of acetylcholine on nicotinic receptors, leading to increased cholinergic ...
George Razay
exaly +2 more sources
Neuropsychiatric Disease and Treatment, 2012 Zhenxin Zhang,1 Lu Yu,2 Maren Gaudig,3 Barbara Schäuble,4 Ute Richarz51Department of Neurology of Peking Union Medical College Hospital, 2Xi’an Janssen Pharmaceutical Ltd, Beijing, China; 3Health Economics and Reimbursement, Janssen ...
Zhang Z +4 more
doaj +1 more source